EX-99.1 2 a11-22971_1ex99d1.htm EX-99.1

Exhibit 99.1

 

FOR:

NUTRACEUTICAL INTERNATIONAL CORPORATION

 

 

CONTACT:

Cory J. McQueen

 

Vice President and

 

Chief Financial Officer

 

(435) 655-6106

 

NUTRACEUTICAL REPORTS FISCAL 2011 Q3 RESULTS

 

PARK CITY, Utah, Jul 28/PRNewswire/—Nutraceutical International Corporation (NASDAQ:  NUTR) today reported results for the fiscal 2011 third quarter ended June 30, 2011.  Net sales for the fiscal 2011 third quarter were $47.5 million compared to $44.5 million for the same quarter of fiscal 2010.  For the third quarter of fiscal 2011, net income was $3.9 million, or $0.38 diluted earnings per share, compared to net income of $3.8 million, or $0.36 diluted earnings per share, for the same quarter of fiscal 2010.

 

Net sales for the nine months ended June 30, 2011 were $142.2 million compared to $137.2 million for the same period in fiscal 2010.  For the nine months ended June 30, 2011, net income was $12.4 million, or $1.19 diluted earnings per share, compared to net income of $12.8 million, or $1.22 diluted earnings per share, for the same period of fiscal 2010.

 

Operating cash flow for the nine months ended June 30, 2011 was $21.3 million compared to $13.3 million for the same period of fiscal 2010.  This operating cash flow was primarily used to invest $9.3 million in acquisitions of branded natural product businesses, $9.2 million in purchases of property and equipment, $1.9 million in repurchases of common stock and $1.0 million to repay net borrowings on the Company’s revolving credit facility.

 

Bill Gay, chairman and chief executive officer, commented, “We are pleased with our fiscal 2011 third quarter net sales and net income growth.  Cash flow and EBITDA remained strong despite ongoing expenses associated with the integration of our recently-acquired businesses.  Management continues to focus on controllable expenses in an effort to offset and balance increases associated with utilities, freight and labor.  In this slow-growth environment, acquisitions that are synergistic to our business model remain critical to our long-term success.”

 

Mr. Gay continued, “The business uncertainties associated with the economy have continued to unfavorably impact the perspectives of many of our primary health food store retailers.  Fortunately, long-term loyal consumers of our brands remain eager for the health benefits our products provide them.  Management believes this dichotomy will continue as long as there are no additional economic shocks.  We intend to aggressively promote and market our brands and look for additional ways to reduce or hold costs.  Management remains optimistic about its ability to grow the company and appreciates all those stakeholders that support us in this effort.”

 



 

ABOUT NUTRACEUTICAL

 

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores.  Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.  Our core business strategy is to acquire, integrate and operate businesses in the natural products industry that manufacture, market and distribute branded nutritional supplements.  We believe that the consolidation and integration of these acquired businesses provides ongoing financial synergies through increased scale and market penetration, as well as strengthened customer relationships.

 

We manufacture and sell nutritional supplements and other natural products under numerous brands including Solaray®, KAL®, Nature’s Life®, LifeTime®, Natural Balance®, bioAllers®, Herbs for Kids™, NaturalCare®, Health from the Sun®, Life-flo®, Organix South®, Pioneer® and Monarch Nutraceuticals™.

 

We own neighborhood natural food markets, which operate under the trade names The Real Food Company™, Thom’s Natural Foods™ and Cornucopia Community Market™.  We also own health food stores, which operate under the trade names Fresh Vitamins™ and Granola’s™.

 

We manufacture and/or distribute one of the broadest branded product lines in the industry with over 5,500 SKUs, including over 700 SKUs sold internationally.  We believe that as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

 

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as “believe,” “expects,” “plan,” “intend,” “may,” “will,” “should,” “can,” or “anticipates,” or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements.  Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) unavailability of desirable acquisitions or inability to complete them, (iii) increased costs, including from increased raw material or energy prices, (iv) changes in general worldwide economic or political conditions, (v) adverse publicity or negative consumer perception regarding nutritional supplements, (vi) issues with obtaining raw materials of adequate quality or quantity, (vii) litigation and claims, including product liability, intellectual property and other types,  (viii) disruptions from or following acquisitions including the loss of customers, (ix) increased competition, (x) slow or negative growth in the nutritional supplement industry or the healthy foods channel, (xi) the loss of key personnel or the inability to manage our operations efficiently, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) insurance coverage issues, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies, and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.  Copies of our SEC reports are available upon request from our investor relations department or may be obtained at the SEC’s website (www.sec.gov).

 

© 2011 Nutraceutical Corporation.  All rights reserved.

 

# # #

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited; dollars in thousands)

 

 

 

June 30,

 

September 30,

 

 

 

2011

 

2010

 

Assets

 

 

 

 

 

Current assets, net

 

$

59,725

 

$

58,294

 

Property, plant and equipment, net

 

70,486

 

61,733

 

Goodwill

 

7,163

 

5,338

 

Other non-current assets, net

 

30,619

 

30,966

 

 

 

$

167,993

 

$

156,331

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

Current liabilities

 

$

19,049

 

$

45,673

 

Long-term liabilities

 

28,330

 

1,739

 

Stockholders’ equity

 

120,614

 

108,919

 

 

 

$

167,993

 

$

156,331

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited; dollars in thousands, except per share data)

 

 

 

Three months ended June 30,

 

Nine months ended June 30,

 

 

 

2011

 

2010

 

2011

 

2010

 

Net sales

 

$

47,453

 

$

44,506

 

$

142,245

 

$

137,241

 

Cost of sales

 

23,546

 

21,523

 

69,462

 

65,441

 

Gross profit

 

23,907

 

22,983

 

72,783

 

71,800

 

Operating expenses

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

17,076

 

16,381

 

51,323

 

49,809

 

Amortization of intangible assets

 

419

 

329

 

1,213

 

941

 

Income from operations

 

6,412

 

6,273

 

20,247

 

21,050

 

Interest and other (income) expense, net

 

293

 

147

 

802

 

403

 

Income before provision for income taxes

 

6,119

 

6,126

 

19,445

 

20,647

 

Provision for income taxes

 

2,174

 

2,332

 

7,001

 

7,808

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

3,945

 

$

3,794

 

$

12,444

 

$

12,839

 

 

 

 

 

 

 

 

 

 

 

Net income per common share

 

 

 

 

 

 

 

 

 

Basic

 

$

0.38

 

$

0.37

 

$

1.20

 

$

1.23

 

Diluted

 

0.38

 

0.36

 

1.19

 

1.22

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

 

 

 

 

 

 

 

Basic

 

10,302,791

 

10,386,829

 

10,350,808

 

10,420,505

 

Diluted

 

10,365,783

 

10,493,005

 

10,417,839

 

10,514,073

 

 



 

NUTRACEUTICAL INTERNATIONAL CORPORATION

EBITDA SCHEDULE

(unaudited; dollars in thousands)

 

 

 

Three months ended June 30,

 

Nine months ended June 30,

 

 

 

2011

 

2010

 

2011

 

2010

 

 

 

 

 

 

 

 

 

 

 

Net income

 

$

3,945

 

$

3,794

 

$

12,444

 

$

12,839

 

Provision for income taxes

 

2,174

 

2,332

 

7,001

 

7,808

 

Interest and other (income) expense, net (1)

 

293

 

147

 

802

 

403

 

Depreciation and amortization

 

2,023

 

1,913

 

5,998

 

5,440

 

 

 

 

 

 

 

 

 

 

 

EBITDA

 

$

8,435

 

$

8,186

 

$

26,245

 

$

26,490

 

 


(1)   Includes amortization of deferred financing fees.

 

Non-GAAP Financial Measures

 

EBITDA (a non-GAAP measure) is defined in our debt covenants and performance measures as earnings before net interest and other (income) expense, taxes, depreciation and amortization.  We believe that EBITDA provides useful additional information to analysts, creditors, investment bankers and management regarding operating performance and debt covenant compliance.  EBITDA has some inherent limitations in measuring operating performance due to the exclusion of certain financial elements such as depreciation and amortization and is not necessarily comparable to other similarly-titled captions of other companies due to potential inconsistencies in the method of calculation.  Furthermore, EBITDA is not intended to be an alternative to net income in determining our operating performance in accordance with generally accepted accounting principles.